Search filters

Copytrend Group acquires 100% in ZAP Holding AG

Copytrend Group, one of the leading Swiss companies active in digital printing, business process outsourcing and web-to-print, acquired 100% in ZAP Holding AG and its subsidiaries Abächerli Media AG, Schlüssel Druck AG, Im Bösch...

Anaveon closes CHF 35 m Series A financing

Anaveon, an immuno-oncology biotech, has successfully concluded a Series A financing round led by Syncona, a UK Life Sciences fund, and joined by the Novartis Venture Fund. The company was founded with financing from BaseLaunch,...

Strategic alliance between Embassy Jewel AG and Kirchhofer Group

VISCHER advised Bregal Unternehmerkapital on the establishment of a strategic alliance between Embassy Jewel AG (controlled by Bregal Unternehmerkapital) and the Kirchhofer Group (family-owned) to become one of the two leading...

Control4 acquires 100% in NEEO AG

Control4 Corporation (NASDAQ:CTRL), a leading global provider of smart home solutions, acquired 100% in NEEO AG. NEEO AG is the Swiss based creator of an acclaimed smart home remote.   VISCHER advised Control4 on all legal aspects...

Orell Füssli Thalia acquires 70% stake in Delivros AG

Orell Füssli Thalia AG acquires a 70% stake in educational media distributor Delivros AG. The B2B divisions of Orell Füssli Thalia and Delivros were merged and the joint venture was renamed Delivros Orell Füssli AG. As a result of...

Success in OTC-derivatives dispute before the Federal Supreme Court

On 16 September 2016, the District Court of Zurich fully dismissed the objection by the two single largest third-party creditors against the schedule of claims of Lehman Brothers Finance AG in liquidation. The Supreme Court of the...

Oculis raises CHF 15.5 million in an extension of its Series B Financing

Oculis SA, a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments in Lausanne, has successfully raised a further CHF 15.5 million in an extension of its Series B financing round...

Oculis in-licenses novel phase II-stage Anti-TNF alpha antibody fragment

Oculis SA, a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments in Lausanne, has entered into an agreement to in license a novel topical anti-TNF alpha antibody from Novartis. The...

AFINUM acquires majority stake in evitria AG

AFINUM Achte Beteiligungsgesellschaft mbH & Co. KG acquired a majority stake in the Schlieren (Switzerland) based biotech company evitria AG from its founder. evitria AG is one of the leading providers of custom antibodies for...

AC Immune and Lilly announce license and collaboration agreement

AC Immune SA (NASDAQ: ACIU) and Eli Lilly and Company (NYSE:LLY) have signed a license and collaboration agreement to research and develop tau aggregation inhibitor small molecules for the potential treatment of Alzheimer’s...

You are currently offline. Some pages or content may fail to load.